Saturday 17 October 2026 Export WRBY’s income statement to Excel — free account

Warby Parker Inc.

WRBY Healthcare Medical Instruments & Supplies

Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024. In the quarter to June 2026, revenue grew 9.81%, EPS grew 379.7% and free cash flow fell 71.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

23.40 1.19 −4.84%

Follow WRBY

Alert me

Market cap: $3.0B
P/E: 334×
Fwd P/E: 122×
Dividend yield: —
F-score: 6/9
Altman Z: 4.73
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 50.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	5	6	—	2	1	2	3	5	—	—	2

Insider Ownership 17.55%

Capital & Financial Ratios $m

Market Cap 3,040.00

Revenue 911.61

Net Income 7.74

Free Cash Flow 21.75

Net Debt (292.67)

Current Ratio 2.27

Debt/Equity 0.00

P/E ratio 334.29

Fwd P/E 122.00

P/S ratio 3.18

P/B ratio 7.40

Past 5Y EPS Growth —

This Y EPS Growth 18.58%

Next Y EPS Growth 44.76%

Next Y revenue growth 11.38%

Next 5Y EPS Growth 38.35%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.28%

10-year low 10-year high

P/B against its own 10 years 61.48%

10-year low 10-year high

EV/Sales against its own 10 years 56.78%

10-year low 10-year high

EV/FCF against its own 10 years 82.72%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	217	254	286	293
Receivables	2	2	3	2
Inventory	62	52	45	42
Other	—	—	—	—
	299	326	352	371

	2023	2024	2025	Q'26
Payables	22	24	32	41
ST’ Debt	—	—	—	—
Other	2	3	4	3
	127	130	150	163

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.23%	13.39%
Cash Flow	—	27.59%	120.24%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	8.66%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	242	236	—	—	—
’25	224	214	222	212	872
’24	200	188	192	191	771
’23	172	166	170	162	670
’22	153	150	149	146	598
’21	139	132	137	133	541
’20	—	67	104	113	394

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	25	30	—	—	—
’25	29	40	18	23	111
’24	20	32	27	20	99
’23	9	19	20	14	61
’22	(10)	(4)	1	24	10
’21	(3)	(2)	5	(32)	(32)
’20	—	—	13	19	33

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	8	7	—	—	—
’25	13	24	(2)	8	44
’24	5	14	13	2	35
’23	(4)	7	4	0	7
’22	(26)	(20)	(13)	10	(50)
’21	(12)	(14)	(8)	(46)	(81)
’20	—	—	(1)	14	13

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.03	0.04	—	—	—
’25	0.03	(0.01)	0.05	(0.05)	0.01
’24	(0.02)	(0.06)	(0.03)	(0.06)	(0.17)
’23	(0.09)	(0.14)	(0.15)	(0.16)	(0.54)
’22	(0.30)	(0.28)	(0.21)	(0.18)	(0.96)
’21	0.06	(0.19)	(1.45)	(0.41)	(2.21)
’20	—	(0.11)	(0.78)	(0.04)	(1.05)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	42.03	10.86	9.50	11.35	13.63	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	60.30	47.29	17.88	25.89	31.00
People
People	Employees	—	—	—	—	2,759	3,033	3,032	3,491	3,780	4,036
	Revenue/emp, $m	—	—	—	0.00	0.14	0.18	0.20	0.19	0.20	0.22
Income, $m
Income, $m	Revenue	—	—	—	370	394	541	598	670	771	872
	Gross margin, %	—	—	—	60.22	58.91	58.76	57.02	54.53	55.34	53.97
	EBT	—	—	—	0	(56)	(144)	(110)	(63)	(20)	3
	EBT margin, %	—	—	—	0.07	(14.15)	(26.63)	(18.37)	(9.37)	(2.53)	0.35
	Net income	—	0	—	0	(56)	(144)	(110)	(63)	(20)	2
	Depreciation	—	—	—	15	18	22	32	41	50	54
Per share, $
Per share, $	Revenue	—	—	—	7.07	7.42	7.59	5.20	5.71	6.41	7.11
	Earnings	—	—	—	(0.52)	(1.05)	(2.21)	(0.96)	(0.54)	(0.17)	0.01
	Cash flow	—	—	—	0.41	0.62	(0.45)	0.09	0.52	0.82	0.90
	Capex	—	—	—	(0.62)	(0.38)	(0.68)	(0.52)	(0.46)	(0.53)	(0.55)
	Free cash flow	—	—	—	(0.21)	0.24	(1.13)	(0.43)	0.06	0.29	0.36
	Book value	—	—	—	0.00	(3.74)	4.01	2.49	2.57	2.82	3.00
	Shares, m	—	—	—	52	53	71	115	117	120	123
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	1,387.90
	P/S	—	—	—	6.04	6.04	6.13	2.75	2.61	3.78	3.07
	P/B	—	—	—	0.00	0.00	11.60	5.75	5.80	8.57	7.27
	EV/Sales	—	—	—	5.50	5.50	5.66	2.41	2.29	3.45	2.74
	EV/FCF	—	—	—	(196.95)	(196.95)	(38.02)	(28.88)	209.32	76.64	54.57
Cash, $m
Cash, $m	Operating cash flow	—	—	—	21	33	(32)	10	61	99	111
	Capex	—	—	—	(33)	(20)	(49)	(60)	(54)	(64)	(67)
	Free cash flow	—	—	—	(11)	13	(81)	(50)	7	35	44
Balance, $m
Balance, $m	Working capital	—	—	—	16	255	210	165	172	196	202
	Total debt	—	—	—	—	—	—	173	—	—	—
	Net debt	—	—	—	(55)	(314)	(256)	(209)	(217)	(254)	(286)
	Shareholders’ equity	—	—	—	—	(198)	286	287	302	340	368
Returns, %
Returns, %	ROA	—	—	—	0.00	(25.15)	(35.56)	(21.87)	(11.00)	(3.24)	0.23
	ROIC	—	—	—	0.00	0.00	(303.52)	(89.04)	(53.00)	(21.91)	(4.10)
	ROE	—	—	—	29.69	28.86	(358.15)	(38.56)	(21.48)	(6.35)	0.46

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MMSI Merit Medical Systems, Inc.	$5.4B	36.4×	23.4×	+9.51% (above 0%: growing)	+18.18% (above 0%: growing)	−25.66% (below 0%: shrinking)	51.37%	14.42%	Compare
STVN Stevanato Group S.p.A.	$5.3B	33.8×	27.5×	+10.46% (above 0%: growing)	−25.00% (below 0%: shrinking)	−167.02% (below 0%: shrinking)	28.75%	12.93%	Compare
ICUI ICU Medical, Inc.	$4.2B	136×	49.5×	+0.51% (above 0%: growing)	−46.85% (below 0%: shrinking)	+655.98% (above 0%: growing)	42.61%	7.09%	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%
ATRC AtriCure, Inc.	$2.9B	259×	591×	+12.83% (above 0%: growing)	n/m	−2.79% (below 0%: shrinking)	77.23%	6.29%	Compare
LMAT LeMaitre Vascular, Inc.	$1.9B	27.9×	31.5×	+9.57% (above 0%: growing)	+22.95% (above 0%: growing)	−27.95% (below 0%: shrinking)	72.13%	28.98%	Compare
XRAY DENTSPLY SIRONA Inc.	$1.8B	— (loss-making)	27.0×	−4.06% (below 0%: shrinking)	n/m	+252.94% (above 0%: growing)	54.90%	9.13%	Compare
Median of peers	$3.5B	37.6×	27.5×	+9.54%	+18.18%	−14.22%	53.14%	10.06%

All 55 Medical Instruments & Supplies stocks →

Warby Parker Inc. (WRBY) key facts

Strength: Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
Warby Parker Inc. (WRBY) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, WRBY traded at $23.40, a market capitalization of $3.0 billion.
Return on equity was 0.46% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 4.73 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.